Boston: strong Swiss presence at the Swiss Biotech pavilion

Swissnex Boston is dedicated to supporting Swiss startups to realize their internalization goals by engaging them in conversations with potential partners. The swissnex team also offers means through which startups can scale to maximize their outreach to penetrate markets, forge partnerships, and receive valuable feedback from world leaders.

As part of their contribution for Swiss startups, the team is organizing the Swiss Start-up Corner within the Swiss Biotech Pavilion – empowered by the Swiss Biotech Association (SBA) and Switzerland Global Enterprise (S-GE). The Swiss startup Corner is organized within the BIO International Convention, an annual event, which brings together more than 1,100 biotechnology companies, academic institutions, and state biotechnology centers across the United States, and in more than 30 other nations. Bio will be held on June 4-7, 2018.

The Swiss Start-up Corner provides a platform to key research institutions and start-ups from Switzerland and is ideal to present and promote startups' activities, allow them to disseminate up-to-date information, foster networking and establish new business partnerships.

“Attending BIO is an opportunity that swissnex Boston offers to startups that otherwise would not have had the financial and project management bandwidth that is necessary to make this happen. Additionally, our extended network guarantees that they can meet the right people and attend targeted events during their visit,” says Philippe Labouchère, Project Leader for Innovation and Entrepreneurship at swissnex Boston.

This year seven biotech startups will represent Switzerland. These include

CDR Life (ZH) – develops therapeutic antibody fragments for high need diseases in immuno-oncology and ophthalmology.

Cellerys (ZH) – the clinical stage startups aims to induce antigen-specific tolerance in multiple sclerosis through peptide –couple therapy.

Cutiss (ZH) – its product denovoSkin, is a personalized bioengineered skin graft for treatment of skin defects and minimizes scarring after transplantation.

DispenCell (VD) – developed and patented an impedance-based technology that allows scientists to isolate single cells reliably and cost-effectively by reducing lab time and validation time.

Elthera (ZG) – develops the first-in-class antibody against the novel target LCAM using a personalized healthcare approach.

Haya Therapeutics – is developing novel first-in-class RNA-based therapies with a specific focus on long noncoding RNAs for the treatment of heart failure.

Simplicity Bio – developed BOSS, a machine-learning platform for translational medicine. BOSS analyses your biological, clinical, digital data streams to extract knowledge and insight that can lead to disease mechanism understanding, drug target discovery, biomarker identification, patient stratification, and drug repositioning.

(ran)